{
    "clinical_study": {
        "@rank": "67310", 
        "arm_group": [
            {
                "arm_group_label": "Control arm", 
                "arm_group_type": "No Intervention", 
                "description": "no medication or acetaminophen"
            }, 
            {
                "arm_group_label": "NSAIDS (ketorolac intravenous, ibuprofen)", 
                "arm_group_type": "Experimental", 
                "description": "ketorolac IV (just before surgery) and ibuprofen for 1 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "It is increasingly recognized the NSAIDS (nonsteroidal antiinflammatory drug) might prevent\n      the several cancers. In breast cancer, the role of NSAIDS (nonsteroidal antiinflammatory\n      drug) has been suggested.However, there was no consistent results.  surgery is main cause of\n      inflammation for cancer patients. Therefore, we want to know the association between\n      prevention of perioperative inflammation with NSAIDS and breast cancer outcomes."
        }, 
        "brief_title": "Perioperative Inflammation and Breast Cancer Outcome", 
        "condition": "Breast Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms", 
                "Inflammation"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Breast cancer patients who took the surgery\n\n        Exclusion Criteria:\n\n          -  underlying medical disease (major heart disease, lung disease, coagulopathy)\n\n          -  major psychologic disease (major depression, schizophrenia, manic disorder)\n\n          -  pregnancy\n\n          -  rheumatic disease patients"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1568", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02141139", 
            "org_study_id": "2009-11-036"
        }, 
        "intervention": {
            "arm_group_label": "NSAIDS (ketorolac intravenous, ibuprofen)", 
            "intervention_name": "NSAIDS (ketorolac and ibuprofen)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Inflammatory Agents", 
                "Ibuprofen", 
                "Ketorolac", 
                "Ketorolac Tromethamine", 
                "Anti-Inflammatory Agents, Non-Steroidal"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Anti-Inflammatory Agents, Non-Steroidal", 
            "Inflammation", 
            "Perioperative Period"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "contact": {
                "email": "sekyung.lee@samsung.com", 
                "last_name": "Se Kyung Lee, M.D.", 
                "phone": "82-10-3014-0110"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "135-710"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Suppression of Inflammation by Using NSAIDs During Peri-operative Period Can Affect the Prognosis of Breast Cancer.", 
        "other_outcome": {
            "measure": "neutrophil-lymphocyte ratio  (NLR), albumin, inflammatory blood lab (CRP)", 
            "safety_issue": "No", 
            "time_frame": "POD 1-2 weeks (immediate postoperative period)"
        }, 
        "overall_contact": {
            "email": "sekyung.lee@samsung.com", 
            "last_name": "Se Kyung Lee, M.D.", 
            "phone": "82-10-3014-0110"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "disease free survival", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02141139"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Seok Jin Nam", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "5years"
        }, 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}